Evidence map›Paper›PMID 22456451›Full record

Trial reportNeuro-degenerative diseases2012

Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease.

Donald G McLaren, Aishwarya Sreenivasan, Eli L Diamond, Meghan B Mitchell, Koene R A Van Dijk, Amy N Deluca, Jacqueline L O'Brien, Dorene M Rentz, Reisa A Sperling, Alireza Atri

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuro-degenerative diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Integrated cerebellar radiomic-network model for predicting mild cognitive impairment in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Aging, Neurodegenerative Disorders, and Cerebellum.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Donald G McLarenDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Aishwarya Sreenivasan
Eli L Diamond
Meghan B Mitchell
Koene R A Van Dijk
Amy N Deluca
Jacqueline L O'Brien
Dorene M Rentz
Reisa A Sperling
Alireza Atri
Massachusetts General Hospital · USHarvard University · USAthinoula A. Martinos Center for Biomedical Imaging · US

Funding

THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BETENSKY, REBECCA A. · 1985 to 2018
$42.1M
Evolution of memory-related fMRI activation over the course of MCI and ADR01AG027435 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, KEITH A., SPERLING, REISA A. · 2006 to 2016
$8.6M
Mentoring Imaging Research in Early ADK24AG035007 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SPERLING, REISA A. · 2010 to 2020
$1.4M
Modeling cholinergic modulation of fMRI memory networks in aging & MCIK23AG027171 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI ATRI, ALIREZA · 2006 to 2010
$805k
NIA NIH HHS K23 AG027171NIA NIH HHS K24 AG035007NIA NIH HHS P50 AG005134NIA NIH HHS P50 AG05134NIA NIH HHS R01 AG027435
6 · The paper itself

Abstract

backgroundPrevious studies have revealed that functional magnetic resonance imaging (fMRI) blood oxygen level-dependent (BOLD) signal in specific brain regions correlates with cross-sectional performance on standardized clinical trial measures in Alzheimer's disease (AD); however, the relationship between longitudinal change in fMRI-BOLD signal and neuropsychological performance remains unknown.

objectiveTo identify changes in regional fMRI-BOLD activity that tracks change in neuropsychological performance in mild AD dementia over 6 months.

methodsTwenty-four subjects (mean age 71.6) with mild AD dementia (mean Mini Mental State Examination 21.7, Global Clinical Dementia Rating 1.0) on stable donepezil dosing participated in two task-related fMRI sessions consisting of a face-name paired associative encoding memory paradigm 24 weeks apart during a randomized placebo-controlled pharmaco-fMRI drug study. Regression analysis was used to identify regions where the change in fMRI activity for Novel > Repeated stimulus contrast was associated with the change scores on postscan memory tests and the Free and Cued Selective Reminding Test (FCSRT).

resultsCorrelations between changes in postscan memory accuracy and changes in fMRI activity were observed in regions including the angular gyrus, parahippocampal gyrus, inferior frontal gyrus and cerebellum. Correlations between changes in FCSRT-free recall and changes in fMRI were observed in regions including the inferior parietal lobule, precuneus, hippocampus and parahippocampal gyrus.

conclusionChanges in encoding-related fMRI activity in regions implicated in mnemonic networks correlated with changes in psychometric measures of episodic memory retrieval performed outside the scanner. These exploratory results support the potential of fMRI activity to track cognitive change and detect signals of short-term pharmacologic effect in early-phase AD studies.

Indexed as

Magnetic Resonance ImagingNeuropsychological TestsAgedAlzheimer DiseaseBrain MappingCognitionDonepezilDopamine AgentsFemaleHumansIndansLongitudinal StudiesMaleMemantineNootropic AgentsOxygenDonepezilDopamine AgentsIndansMemantineNootropic AgentsOxygenPiperidines

Identifiers

PMID22456451
PMCPMC3369254
OpenAlexW2093576807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.